5657-41-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(carbamoylamino)benzenesulfonamide is utilized as a pharmaceutical intermediate for the synthesis of various drugs, particularly antibiotics and antifungal agents, due to its ability to inhibit bacterial dihydrofolic acid synthesis, which is vital for nucleic acid production.
Used in Anti-inflammatory Applications:
4-(carbamoylamino)benzenesulfonamide is employed as an anti-inflammatory agent for its potential in treating conditions such as rheumatoid arthritis and other inflammatory diseases, leveraging its capacity to reduce inflammation and alleviate symptoms associated with these conditions.

Upstream product

• 64-10-8 phenyl carbamate 
• 40685-78-7 N-[4-(chlorosulfonyl)phenyl]urea 
• 67080-96-0 N-acetyl-N'-(4-sulfamoyl-phenyl)-urea 
• 91772-10-0 N-cyano-sulfanilic acid amide 
• 556-89-8 nitrourea 
• 63-74-1 sulfanilamide 
• 590-28-3 potassium cyanate 
• 15009-93-5 N-<4-Sulfamoyl-phenyl>-N'--harnstoff 
• 917-61-3 sodium isocyanate 
• 64-19-7 acetic acid 
• 67080-67-5 N-acetylcarbamoyl-sulfanilyl chloride 
• 102-03-4 1-acetyl-3-phenylurea 

Relevant academic research and scientific papers

Carbonic anhydrase inhibitors: Design, synthesis, and biological evaluation of novel sulfonyl semicarbazide derivatives

A series of novel sulfonyl semicarbazides 5-13 was designed, synthesized, and evaluated for human carbonic anhydrase (hCA) inhibition. The new sulfonyl semicarbazides were tested against a panel of hCA isoforms I, II, IX, and XII, using acetazolamide (AZA

4-Sulphamoylphenyl semicarbazones with anticonvulsant activity

A series of 4-sulphamoylphenyl semicarbazone derivatives were prepared starting from sulphanilamide and screened for anticonvulsant activity. The results indicated that greater protection was obtained in the maximal electroshock screen (MES) and subcutane

Inhibition of carbonic anhydrase isoforms I, II, IX and XII with Schiff's bases incorporating iminoureido moieties

A series of new Schiff's bases was obtained from the sulfanilamide semicarbazone (4-aminosulfonylphenyl semicarbazide) and aromatic/heterocyclic aldehydes. The new compounds were designed to incorporate moieties known to induce effective inhibitory activi

Aryl-4,5-dihydro-1H-pyrazole-1-carboxamide derivatives bearing a sulfonamide moiety show single-digit nanomolar-to-subnanomolar inhibition constants against the tumor-associated human carbonic anhydrases IX and XII

A series of new 3-phenyl-5-aryl-N-(4-sulfamoylphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide derivatives was designed here, synthesized, and studied for carbonic anhydrase (CAs, EC 4.2.1.1) inhibitory activity against the human (h) isozymes I, II, and VII (cytosolic, off-target isoforms), and IX and XII (anticancer drug targets). Generally, CA I was not effectively inhibited, whereas effective inhibitors were identified against both CAs II (KIs in the range of 5.2-233 nM) and VII (KIs in the range of 2.3-350 nM). Nonetheless, CAs IX and XII were the most susceptible isoforms to this class of inhibitors. In particular, compounds bearing an unsubstituted phenyl ring at the pyrazoline 3 position showed 1.3-1.5 nM KIs against CA IX. In contrast, a subset of derivatives having a 4-halo-phenyl at the same position of the aromatic scaffold even reached subnanomolar KIs against CA XII (0.62-0.99 nM). Docking studies with CA IX and XII were used to shed light on the derivative binding mode driving the preferential inhibition of the tumor-associated CAs. The identified potent and selective CA IX/XII inhibitors are of interest as leads for the development of new anticancer strategies.